307 related articles for article (PubMed ID: 16874853)
21. Fibrates and cholestasis.
Ghonem NS; Assis DN; Boyer JL
Hepatology; 2015 Aug; 62(2):635-43. PubMed ID: 25678132
[TBL] [Abstract][Full Text] [Related]
22. Primary biliary cirrhosis and bile acids.
Corpechot C
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S13-20. PubMed ID: 23141888
[TBL] [Abstract][Full Text] [Related]
23. [Bile formation and cholestasis].
Jansen PL; Müller M; Kuipers F
Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2384-91. PubMed ID: 11145092
[TBL] [Abstract][Full Text] [Related]
24. Ursodeoxycholic acid in chronic liver disease.
de Caestecker JS; Jazrawi RP; Petroni ML; Northfield TC
Gut; 1991 Sep; 32(9):1061-5. PubMed ID: 1916492
[TBL] [Abstract][Full Text] [Related]
25. The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function.
Shoda J; Kano M; Oda K; Kamiya J; Nimura Y; Suzuki H; Sugiyama Y; Miyazaki H; Todoroki T; Stengelin S; Kramer W; Matsuzaki Y; Tanaka N
Am J Gastroenterol; 2001 Dec; 96(12):3368-78. PubMed ID: 11774951
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease.
Paumgartner G; Beuers U
Clin Liver Dis; 2004 Feb; 8(1):67-81, vi. PubMed ID: 15062194
[TBL] [Abstract][Full Text] [Related]
27. The pathophysiology of cholestasis with special reference to primary biliary cirrhosis.
Jansen PL
Baillieres Best Pract Res Clin Gastroenterol; 2000 Aug; 14(4):571-83. PubMed ID: 10976015
[TBL] [Abstract][Full Text] [Related]
28. Cell Death and microRNAs in Cholestatic Liver Diseases: Update on Potential Therapeutic Applications.
Castro RE; Rodrigues CMP
Curr Drug Targets; 2017; 18(8):921-931. PubMed ID: 26477457
[TBL] [Abstract][Full Text] [Related]
29. [Cholestatic liver diseases].
Reichel C; Meier-Abt PJ
Ther Umsch; 1997 Nov; 54(11):639-44. PubMed ID: 9454366
[TBL] [Abstract][Full Text] [Related]
30. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
31. The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease.
Luketic VA; Sanyal AJ
Gastroenterologist; 1994 Mar; 2(1):74-9. PubMed ID: 8055235
[TBL] [Abstract][Full Text] [Related]
32. [Bile acids in the process of canalicular bile formation].
Sinel'nik TB; Sinel'nik OD; Ribal'chenko VK
Fiziol Zh (1994); 2003; 49(6):80-93. PubMed ID: 14965044
[TBL] [Abstract][Full Text] [Related]
33. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.
Moustafa T; Fickert P; Magnes C; Guelly C; Thueringer A; Frank S; Kratky D; Sattler W; Reicher H; Sinner F; Gumhold J; Silbert D; Fauler G; Höfler G; Lass A; Zechner R; Trauner M
Gastroenterology; 2012 Jan; 142(1):140-151.e12. PubMed ID: 22001865
[TBL] [Abstract][Full Text] [Related]
34. [Effect of ursodeoxycholic acid treatment on primary biliary cirrhosis].
Raedsch R; Stiehl A; Hopf U; Möller B
Z Gastroenterol Verh; 1989 Jul; 24():125-7. PubMed ID: 2474923
[No Abstract] [Full Text] [Related]
35. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
Paumgartner G; Beuers U
Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of cholestatic hepatic diseases: more than the substitution of fat soluble vitamins?].
Pausch J; Gatzen M
Internist (Berl); 2006 Dec; 47(12):1239-40, 1242-4. PubMed ID: 17077981
[TBL] [Abstract][Full Text] [Related]
37. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
Beuers U
Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551
[TBL] [Abstract][Full Text] [Related]
38. [Molecular mechanisms of bile formation and cholestatic diseases].
Poupon R
Bull Acad Natl Med; 2003; 187(7):1261-74; discussion 1274-6. PubMed ID: 15146603
[TBL] [Abstract][Full Text] [Related]
39. Nuclear receptors as therapeutic targets in cholestatic liver diseases.
Zollner G; Trauner M
Br J Pharmacol; 2009 Jan; 156(1):7-27. PubMed ID: 19133988
[TBL] [Abstract][Full Text] [Related]
40. Hepatocellular transporters and cholestasis.
Pauli-Magnus C; Meier PJ
J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S103-10. PubMed ID: 15758645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
